Radiopharm Theranostics (RDPTF) Shares Outstanding (2023 - 2026)

Radiopharm Theranostics (RDPTF) has reported Shares Outstanding (Entity) for 3 consecutive years, with $2.4 billion the latest figure, recorded in Q2 2025.

• On a quarterly basis, Shares Outstanding (Entity) rose 413.71% year-over-year to $2.4 billion in Q2 2025; TTM through Jun 2025 was $2.4 billion, a 413.71% increase from a year earlier, with the FY2025 full-year figure at $2.4 billion, up 413.71% from the prior year.
• Shares Outstanding (Entity) was $2.4 billion for Q2 2025 at Radiopharm Theranostics, up from $460.4 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $2.4 billion in Q2 2025 and troughed at $339.3 million in Q2 2023.
• A 3-year average of $1.1 billion and a median of $460.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) surged 35.68% in 2024 and surged 413.71% in 2025, its largest moves.
• Over 3 years, Shares Outstanding (Entity) stood at $339.3 million in 2023, then surged by 35.68% to $460.4 million in 2024, then surged by 413.71% to $2.4 billion in 2025.
• The last three Shares Outstanding (Entity) figures came in at $2.4 billion (Q2 2025), $460.4 million (Q2 2024), and $339.3 million (Q2 2023), per Business Quant data.